AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇹🇳
EMICIZUMAB in Tunisia
4 products registered with DPM — 0 active, 4 expired
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| HEMLIBRA Solution injectable / 30mg/ml | 6993235H | Roche Pharma (Schweiz) AG | expired | 7 Mar 2022 |
| HEMLIBRA Solution injectable / 150mg/ml | 6993234H | Roche Pharma (Schweiz) AG | expired | 7 Mar 2022 |
| HEMLIBRA Solution injectable / 105 mg / 0,7ml | 6993233H | Roche Pharma (Schweiz) AG | expired | 7 Mar 2022 |
| HEMLIBRA Solution injectable / 60 mg / 0,4ml | 6993232H | Roche Pharma (Schweiz) AG | expired | 7 Mar 2022 |
EMICIZUMAB — DPM Registration Details
DPM (Tunisia) has 4 registered products containing EMICIZUMAB, of which 0 are currently active. Data is sourced directly from the official DPM drug register and refreshed daily.
Track EMICIZUMAB registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.